Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) granted equity inducement awards on June 2, 2026 under its 2024 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
The awards cover 28,800 stock options at a $31.26 exercise price and 14,150 RSUs for ten new employees, vesting over four years.
Vera Therapeutics (Nasdaq: VERA) announced U.S. FDA alignment on an earlier ORIGIN Phase 3 eGFR analysis for atacicept in adults with IgA nephropathy (IgAN).
The BLA for accelerated approval has a PDUFA date of July 7, 2026. eGFR results are expected in Q3 2026, supporting a planned sBLA in Q4 2026 and potential full approval in 2027.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted May 4, 2026 to ten new employees under its 2024 Inducement Plan. The Compensation Committee granted non-qualified stock options for 40,250 shares and RSUs underlying 20,125 shares.
Each option has an exercise price of $35.51 (closing price May 4, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest 25% annually beginning May 20, 2026. Awards are subject to the Inducement Plan and individual award agreements.
Vera Therapeutics (NASDAQ: VERA) reported Q1 2026 results and a business update. The FDA granted Priority Review to the atacicept BLA for IgA nephropathy with a PDUFA date of July 7, 2026. The company expects a potential U.S. commercial launch in mid-2026, pending approval. Vera reported a Q1 net loss of $121.0 million and held $596.8 million in cash, equivalents and marketable securities as of March 31, 2026, which it says is sufficient to fund operations through potential approval and launch. Leadership promotions and hires were announced, and clinical readouts are expected in Q2 2026 and Q1 2027.
Vera Therapeutics (Nasdaq: VERA) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12–14, 2026. Management presentation is scheduled for May 13, 2026 at 4:20 PM PDT, and management will hold one-on-one investor meetings.
A live webcast is available at the provided URL and a replay will be accessible for 90 days via the company’s Investor Calendar. According to the company, the presentation is part of its investor outreach during the conference.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted April 8, 2026 to 89 new employees under its 2024 Inducement Plan. The Compensation Committee approved non-qualified stock options for 258,200 shares and RSUs underlying 131,925 shares.
Options carry an exercise price of $40.33 per share (closing price on April 8, 2026) and vest over four years; RSUs vest annually over four years beginning May 20, 2026.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for its newly hired Chief Legal Officer, Jane Wright-Mitchell, approved March 23, 2026 under the 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The grants include non-qualified stock options to purchase 56,850 Class A shares at an exercise price of $40.73 (Vera's March 23 closing price) and restricted stock units underlying 42,403 Class A shares. Options vest over four years (25% at first anniversary, then monthly over 36 months). RSUs vest 25% on each anniversary beginning May 20, 2026. Awards are subject to the Inducement Plan and award agreements.
Vera Therapeutics (Nasdaq: VERA) appointed Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer effective March 25, 2026. Ms. Wright-Mitchell joins with over 25 years of life‑sciences legal and compliance experience and prior roles including general counsel and chief compliance officer.
She previously advised Vera as a strategic legal consultant and will lead legal efforts supporting regulatory approvals, commercialization, intellectual property management, and the potential launch of atacicept for IgA nephropathy.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards on March 3, 2026 under its 2024 Inducement Plan to six new employees. The grants include 46,000 non‑qualified stock options and 25,875 RSUs.
Options have an exercise price of $39.30 (closing price on March 3, 2026); options and RSUs vest over four years with 25% after one year and remaining vesting monthly or on annual anniversaries (Feb 20 or May 20, 2026) as applicable.
Vera Therapeutics (Nasdaq: VERA) appointed Christopher Hite to its Board of Directors effective March 5, 2026. Mr. Hite will serve as an independent director and brings over 25 years of strategic and financial leadership in biopharma, currently serving as Executive Vice President and Vice Chairman at Royalty Pharma.
The appointment coincides with Vera Therapeutics preparing for the potential launch of its dual BAFF/APRIL inhibitor atacicept for IgA nephropathy later in 2026, and management says Hite will support the company’s commercial and financial strategy.